$ARTV News

Artiva Biotherapeutics: Targeting A Potentially Lucrative Niche

Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Artiva Biotherapeutics Files Prospectus To Offer Up To $400M In Securities

Artiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Artiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

Needham Reiterates Buy on Artiva Biotherapeutics, Maintains $41 Price Target

Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today

Artiva Biotherapeutics Announces Clinical, Safety And Translational Data For AlloNK, Its Allogeneic, Non-Genetically Modified Natural Killer Cell Therapy Candidate

Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic Diseases

Artiva Biotherapeutics Announces Data Presentations On Allogenic NK Cell Therapy June 3-6

Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development

Needham Maintains Buy on Artiva Biotherapeutics, Raises Price Target to $41

Cantor Fitzgerald Maintains Overweight on Artiva Biotherapeutics, Raises Price Target to $40

Wedbush Maintains Outperform on Artiva Biotherapeutics, Raises Price Target to $40

Artiva Biotherapeutics: 'Buy' On AlloNK POC And FDA Phase 3 Alignment For Refractory RA

HC Wainwright & Co. Maintains Buy on Artiva Biotherapeutics, Raises Price Target to $35

Artiva Biotherapeutics Stock Slides Despite Positive Trial Data

Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights